MedTrace Logo

To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

NCT04945616 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-07-01

No results posted yet for this study

Summary

The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender. The subjects are divided into three groups: A, B, and C, with 16 cases in each of groups A and B, and 20 cases in group C.

Conditions

Interventions

DRUG

Aspirin、clopidogrel、placebo or SHR2285

groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；

DRUG

Aspirin、clopidogrel、placebo or SHR2285

groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)

DRUG

Aspirin、ticagrelor、placebo or SHR2285

groupC： Aspirin + ticagrelor + placebo or SHR2285

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-13
Primary Completion
2021-10-19
Completion
2022-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04945616 on ClinicalTrials.gov